<p>富蘭克林資源公司在最近向證券交易委員會提交的 13F 文件中披露，在第四季度其在 Olema Pharmaceuticals, Inc.（納斯達克代碼：OLMA - 免費報告）的股份增加了 1,714.9%。該基金在季度內購買了 258,625 股後，持有 273,706 股公司的股票。富蘭克林資源公司在最近一個季度末持有 Olema Pharmaceuticals 約 0.48% 的股份，價值 1,596,000 美元。</p>
<p>獲取 <strong>Olema Pharmaceuticals</strong> 警報：</p>
<p>其他一些機構投資者和對沖基金最近也對 OLMA 的持倉進行了調整。威靈頓管理集團在第四季度將其在 Olema Pharmaceuticals 的股份提高了 52.1%。威靈頓管理集團現在擁有 1,525,484 股公司的股票，價值 8,839,000 美元，在此期間又購買了 522,799 股。施羅德投資管理集團在第四季度將其在 Olema Pharmaceuticals 的股份增加了 548.7%。施羅德投資管理集團現在擁有 533,111 股公司的股票，價值 2,991,000 美元，在上個季度又購買了 450,924 股。Pier Capital LLC 在第四季度購買了 Olema Pharmaceuticals 的新股份，價值約 1,588,000 美元。Pictet 資產管理控股公司在第四季度將其在 Olema Pharmaceuticals 的股份提高了 12.9%。Pictet 資產管理控股公司現在擁有 1,883,354 股公司的股票，價值 10,980,000 美元，在上個季度又收購了 215,895 股。最後，摩根大通在第三季度將其在 Olema Pharmaceuticals 的持股增加了 658.7%。摩根大通現在擁有 181,032 股公司的股票，價值 2,162,000 美元，在此期間又收購了 157,171 股。機構投資者持有公司 91.78% 的股份。</p>
<h2>Olema Pharmaceuticals 股票上漲 7.7%</h2>
<p>週二，OLMA 股票開盤價為 4.06 美元。該公司的 50 日移動平均價為 4.30 美元，200 日移動平均價為 7.21 美元。公司市值為 2.7743 億美元，市盈率為-1.85，貝塔值為 2.10。Olema Pharmaceuticals, Inc.的 52 周最低價為 2.86 美元，最高價為 16.62 美元。</p>
<p>Olema Pharmaceuticals（納斯達克代碼：OLMA - 獲取免費報告）最近於 3 月 18 日（星期二）發佈了季度財報。公司報告季度每股收益為（0.51 美元），超出市場共識預期的（0.63 美元）0.12 美元。分析師預計 Olema Pharmaceuticals, Inc.在本年度的每股收益將為-2.33 美元。</p>
<h2>分析師設定新目標價</h2>
<p>幾位分析師對該股票發表了看法。HC Wainwright 在 3 月 19 日（星期三）的研究報告中重申了對 Olema Pharmaceuticals 的 “買入” 評級，並設定了 30.00 美元的目標價。摩根大通在 3 月 28 日（星期五）的研究報告中將 Olema Pharmaceuticals 的目標價從 30.00 美元下調至 28.00 美元，並對該公司設定了 “增持” 評級。最後，Oppenheimer 在 3 月 19 日（星期三）的研究報告中重申了 “跑贏大盤” 評級，並將 Olema Pharmaceuticals 的目標價設定為 25.00 美元（低於 30.00 美元）。</p>
<p><strong>閲讀我們對 OLMA 的最新分析</strong></p>
<h2>Olema Pharmaceuticals 公司簡介</h2>
<p>（免費報告）</p>
<p>Olema Pharmaceuticals, Inc.是一家臨牀階段的生物製藥公司，專注於女性癌症治療的發現、開發和商業化。其主要產品候選藥物為 OP-1250，一種雌激素受體（ER）拮抗劑和選擇性 ER 降解劑，目前正在進行針對複發性、局部晚期或轉移性雌激素受體陽性、HER2 陰性乳腺癌的第三階段臨牀試驗；同時 OP-1250 與 CDK4/6 抑制劑 palbociclib、ribociclib 和 alpelisib 聯合進行針對複發性、局部晚期或轉移性雌激素受體陽性、HER2 陰性乳腺癌的 1/2 期臨牀試驗，並開發 OPERA-01 用於 ER+/HER2-晚期或轉移性乳腺癌的治療。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票超過 Olema Pharmaceuticals</li>
<li>3 只沃倫·巴菲特在波動時期必須購買的股票</li>
<li>儘管華爾街下調評級，為什麼 NVIDIA 股票可能會飆升</li>
<li>萬億美元市值的意義超越數字</li>
<li>第一季度內部人士購買的三隻大型股票：買入、賣出或持有</li>
<li>便士股票適合你的投資組合嗎？</li>
<li>3 只熱銷新 IPO 逆勢而上，抵禦 2025 年市場下滑</li>
</ul>
<p><strong>想看看其他對沖基金持有的 OLMA 嗎？</strong> 訪問 HoldingsChannel.com 獲取 Olema Pharmaceuticals, Inc.（納斯達克代碼：OLMA - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0xNQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0xNQQ"/></p>
<p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Olema Pharmaceuticals 嗎？</h2>
<p>在你考慮投資 Olema Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就購買，以便在更廣泛的市場注意到之前...而 Olema Pharmaceuticals 並不在名單上。</p>
<p>雖然 Olema Pharmaceuticals 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

OLMA

富蘭克林資源

<p>富蘭克林資源公司在最近向證券交易委員會提交的 13F 文件中表示，在第四季度其在 Olema Pharmaceuticals, Inc.（NASDAQ:OLMA - 免費報告）的股份增加了 1,714.9%</p>

<p>Franklin Resources Inc. grew its stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 1,714.9% during the 4th quarter, according to its most recent 13F filing with the Securities &amp; Exchange Commission. The fund owned 273,706 shares of the company's stock after purchasing an additional 258,625 shares during the quarter. Franklin Resources Inc. owned about 0.48% of Olema Pharmaceuticals worth $1,596,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>富蘭克林資源公司在最近向證券交易委員會提交的 13F 文件中披露，在第四季度其在 Olema Pharmaceuticals, Inc.（納斯達克代碼：OLMA - 免費報告）的股份增加了 1,714.9%。該基金在季度內購買了 258,625 股後，持有 273,706 股公司的股票。富蘭克林資源公司在最近一個季度末持有 Olema Pharmaceuticals 約 0.48% 的股份，價值 1,596,000 美元。</p>
</div><p>Get <strong>Olema Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Olema Pharmaceuticals</strong> 警報：</p>
</div><p>A number of other institutional investors and hedge funds also recently made changes to their positions in OLMA. Wellington Management Group LLP raised its position in shares of Olema Pharmaceuticals by 52.1% in the fourth quarter. Wellington Management Group LLP now owns 1,525,484 shares of the company's stock valued at $8,839,000 after purchasing an additional 522,799 shares during the period. Schroder Investment Management Group grew its stake in Olema Pharmaceuticals by 548.7% in the 4th quarter. Schroder Investment Management Group now owns 533,111 shares of the company's stock valued at $2,991,000 after buying an additional 450,924 shares during the last quarter. Pier Capital LLC bought a new position in Olema Pharmaceuticals in the 4th quarter valued at about $1,588,000. Pictet Asset Management Holding SA lifted its position in Olema Pharmaceuticals by 12.9% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,883,354 shares of the company's stock worth $10,980,000 after acquiring an additional 215,895 shares during the last quarter. Finally, JPMorgan Chase &amp; Co. boosted its holdings in shares of Olema Pharmaceuticals by 658.7% during the third quarter. JPMorgan Chase &amp; Co. now owns 181,032 shares of the company's stock worth $2,162,000 after acquiring an additional 157,171 shares during the period. Institutional investors own 91.78% of the company's stock.</p>
<div class="lb-trans"><p>其他一些機構投資者和對沖基金最近也對 OLMA 的持倉進行了調整。威靈頓管理集團在第四季度將其在 Olema Pharmaceuticals 的股份提高了 52.1%。威靈頓管理集團現在擁有 1,525,484 股公司的股票，價值 8,839,000 美元，在此期間又購買了 522,799 股。施羅德投資管理集團在第四季度將其在 Olema Pharmaceuticals 的股份增加了 548.7%。施羅德投資管理集團現在擁有 533,111 股公司的股票，價值 2,991,000 美元，在上個季度又購買了 450,924 股。Pier Capital LLC 在第四季度購買了 Olema Pharmaceuticals 的新股份，價值約 1,588,000 美元。Pictet 資產管理控股公司在第四季度將其在 Olema Pharmaceuticals 的股份提高了 12.9%。Pictet 資產管理控股公司現在擁有 1,883,354 股公司的股票，價值 10,980,000 美元，在上個季度又收購了 215,895 股。最後，摩根大通在第三季度將其在 Olema Pharmaceuticals 的持股增加了 658.7%。摩根大通現在擁有 181,032 股公司的股票，價值 2,162,000 美元，在此期間又收購了 157,171 股。機構投資者持有公司 91.78% 的股份。</p>
</div><h2>Olema Pharmaceuticals Stock Up 7.7 %</h2>
<div class="lb-trans"><h2>Olema Pharmaceuticals 股票上漲 7.7%</h2>
</div><p>Shares of OLMA stock opened at $4.06 on Tuesday. The firm has a 50 day moving average of $4.30 and a 200-day moving average of $7.21. The company has a market cap of $277.43 million, a price-to-earnings ratio of -1.85 and a beta of 2.10. Olema Pharmaceuticals, Inc. has a 52 week low of $2.86 and a 52 week high of $16.62.</p>
<div class="lb-trans"><p>週二，OLMA 股票開盤價為 4.06 美元。該公司的 50 日移動平均價為 4.30 美元，200 日移動平均價為 7.21 美元。公司市值為 2.7743 億美元，市盈率為-1.85，貝塔值為 2.10。Olema Pharmaceuticals, Inc.的 52 周最低價為 2.86 美元，最高價為 16.62 美元。</p>
</div><p>Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.12. Analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current year.</p>
<div class="lb-trans"><p>Olema Pharmaceuticals（納斯達克代碼：OLMA - 獲取免費報告）最近於 3 月 18 日（星期二）發佈了季度財報。公司報告季度每股收益為（0.51 美元），超出市場共識預期的（0.63 美元）0.12 美元。分析師預計 Olema Pharmaceuticals, Inc.在本年度的每股收益將為-2.33 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>Several analysts have weighed in on the stock. HC Wainwright reiterated a &#34;buy&#34; rating and issued a $30.00 price objective on shares of Olema Pharmaceuticals in a research note on Wednesday, March 19th. JPMorgan Chase &amp; Co. dropped their price target on shares of Olema Pharmaceuticals from $30.00 to $28.00 and set an &#34;overweight&#34; rating for the company in a research report on Friday, March 28th. Finally, Oppenheimer reiterated an &#34;outperform&#34; rating and issued a $25.00 price target (down from $30.00) on shares of Olema Pharmaceuticals in a research note on Wednesday, March 19th.</p>
<div class="lb-trans"><p>幾位分析師對該股票發表了看法。HC Wainwright 在 3 月 19 日（星期三）的研究報告中重申了對 Olema Pharmaceuticals 的 “買入” 評級，並設定了 30.00 美元的目標價。摩根大通在 3 月 28 日（星期五）的研究報告中將 Olema Pharmaceuticals 的目標價從 30.00 美元下調至 28.00 美元，並對該公司設定了 “增持” 評級。最後，Oppenheimer 在 3 月 19 日（星期三）的研究報告中重申了 “跑贏大盤” 評級，並將 Olema Pharmaceuticals 的目標價設定為 25.00 美元（低於 30.00 美元）。</p>
</div><p><strong>Read Our Latest Analysis on OLMA</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 OLMA 的最新分析</strong></p>
</div><h2>Olema Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Olema Pharmaceuticals 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.</p>
<div class="lb-trans"><p>Olema Pharmaceuticals, Inc.是一家臨牀階段的生物製藥公司，專注於女性癌症治療的發現、開發和商業化。其主要產品候選藥物為 OP-1250，一種雌激素受體（ER）拮抗劑和選擇性 ER 降解劑，目前正在進行針對複發性、局部晚期或轉移性雌激素受體陽性、HER2 陰性乳腺癌的第三階段臨牀試驗；同時 OP-1250 與 CDK4/6 抑制劑 palbociclib、ribociclib 和 alpelisib 聯合進行針對複發性、局部晚期或轉移性雌激素受體陽性、HER2 陰性乳腺癌的 1/2 期臨牀試驗，並開發 OPERA-01 用於 ER+/HER2-晚期或轉移性乳腺癌的治療。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Olema Pharmaceuticals</li>
<li>3 Must-Buy Warren Buffett Stocks for Volatile Times</li>
<li>Why NVIDIA Stock Could Soar Despite Wall Street Downgrades</li>
<li>The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number</li>
<li>Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>3 Hot New IPOs Defying the 2025 Market Slump</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 Olema Pharmaceuticals</li>
<li>3 只沃倫·巴菲特在波動時期必須購買的股票</li>
<li>儘管華爾街下調評級，為什麼 NVIDIA 股票可能會飆升</li>
<li>萬億美元市值的意義超越數字</li>
<li>第一季度內部人士購買的三隻大型股票：買入、賣出或持有</li>
<li>便士股票適合你的投資組合嗎？</li>
<li>3 只熱銷新 IPO 逆勢而上，抵禦 2025 年市場下滑</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding OLMA?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有的 OLMA 嗎？</strong> 訪問 HoldingsChannel.com 獲取 Olema Pharmaceuticals, Inc.（納斯達克代碼：OLMA - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0xNQQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=OLMA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Olema Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Olema Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Olema Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮投資 Olema Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Olema Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就購買，以便在更廣泛的市場注意到之前...而 Olema Pharmaceuticals 並不在名單上。</p>
</div><p>While Olema Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Olema Pharmaceuticals 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

富蘭克林資源公司購入了 258,625 股 Olema Pharmaceuticals, Inc.（納斯達克代碼：OLMA）的股票